Diagnostic Image Feature and Performance of CT and Gadoxetic Acid Disodium-Enhanced MRI in Distinction of Combined Hepatocellular- Cholangiocarcinoma from Hepatocellular Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To find diagnostic image features, to compare diagnostic performance of multiphase CT versus gadoxetic acid disodium-enhanced MRI (GAD-MRI), and to evaluate the impact of analyzing Liver Imaging Reporting and Data System (LI-RADS) imaging features, for distinguishing combined hepatocellular-cholangiocarcinoma (CHC) from hepatocellular carcinoma (HCC). Materials and Methods: Ninety-six patients with pathologically proven CHC (n = 48) or HCC (n = 48), diagnosed June 2008 to May 2018 were retrospectively analyzed in random order by three radiologists with different experience levels. In the first analysis, the readers independently determined the probability of CHC based on their own knowledge and experiences. In the second analysis, they evaluated imaging features defined in LI-RADS 2018. Area under the curve (AUC) values for CHC diagnosis were compared between CT and MRI, and between the first and second analyses. Interobserver agreement was assessed using Cohen’s weighted κ values. Results: Targetoid LR-M image features showed better specificities and positive predictive values (PPV) than the others. Among them, rim arterial phase hyperenhancement had the highest specificity and PPV. Average sensitivity, specificity, and AUC values were higher for MRI than for CT in both the first (P = 0.008, 0.005, 0.002, respectively) and second (P = 0.017, 0.026, 0.036) analyses. Interobserver agreements were higher for MRI in both analyses (κ = 0.307 for CT, κ = 0.332 for MRI in the first analysis; κ = 0.467 for CT, κ = 0.531 for MRI in the second analysis), with greater agreement in the second analysis for both CT (P = 0.001) and MRI (P < 0.001). Conclusion: Rim arterial phase hyperenhancement on GAD-MRI can be a good indicator suggesting CHC more than HCC. GAD-MRI may provide greater accuracy than CT for distinguishing CHC from HCC. Interobserver agreement can be improved for both CT and MRI by analyzing LI-RADS imaging features.
Abstract
Purpose: To find diagnostic image features, to compare diagnostic performance of multiphase CT versus gadoxetic acid disodium-enhanced MRI (GAD-MRI), and to evaluate the impact of analyzing Liver Imaging Reporting and Data System (LI-RADS) imaging features, for distinguishing combined hepatocellular-cholangiocarcinoma (CHC) from hepatocellular carcinoma (HCC). Materials and Methods: Ninety-six patients with pathologically proven CHC (n = 48) or HCC (n = 48), diagnosed June 2008 to May 2018 were retrospectively analyzed in random order by three radiologists with different experience levels. In the first analysis, the readers independently determined the probability of CHC based on their own knowledge and experiences. In the second analysis, they evaluated imaging features defined in LI-RADS 2018. Area under the curve (AUC) values for CHC diagnosis were compared between CT and MRI, and between the first and second analyses. Interobserver agreement was assessed using Cohen’s weighted κ values. Results: Targetoid LR-M image features showed better specificities and positive predictive values (PPV) than the others. Among them, rim arterial phase hyperenhancement had the highest specificity and PPV. Average sensitivity, specificity, and AUC values were higher for MRI than for CT in both the first (P = 0.008, 0.005, 0.002, respectively) and second (P = 0.017, 0.026, 0.036) analyses. Interobserver agreements were higher for MRI in both analyses (κ = 0.307 for CT, κ = 0.332 for MRI in the first analysis; κ = 0.467 for CT, κ = 0.531 for MRI in the second analysis), with greater agreement in the second analysis for both CT (P = 0.001) and MRI (P < 0.001). Conclusion: Rim arterial phase hyperenhancement on GAD-MRI can be a good indicator suggesting CHC more than HCC. GAD-MRI may provide greater accuracy than CT for distinguishing CHC from HCC. Interobserver agreement can be improved for both CT and MRI by analyzing LI-RADS imaging features.
참고문헌 (27)
- Brunt E, "cHCC-CCA : consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation", Hepatology, 68, pp.113~126 (2018)
- Ramai D, "Combined hepatocellular cholangiocarcinoma : a population-based retrospective study", Am J Gastroenterol, 114, pp.1496~1501 (2019)
- Cunha GM, "LI-RADS and transplantation: challenges and controversies", Abdom Radiol(NY), 46, pp.29~42 (2021)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma: 2018practice guidance by the American Association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- Fraum TJ, "Assessment of primary liver carcinomas other than hepatocellular carcinoma(HCC)with LI-RADS v2018 : comparison of the LI-RADS target population to patients without LI-RADSdefined HCC risk factors", Eur Radiol, 30, pp.996~1007 (2020)
- Kim MJ, "Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma", Eur Radiol, 29, pp.5101~5110 (2019)
- Potretzke TA, "Imaging features of biphenotypic primary liver carcinoma(hepatocholangiocarcinoma)and the potential to mimic hepatocellular carcinoma : LI-RADS analysis of CT and MRI features in 61 cases", AJR Am J Roentgenol, 207, pp.25~31 (2016)
- Jeon SK, "Combined hepatocellular cholangiocarcinoma : LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging", Eur Radiol, 29, pp.373~382 (2019)
- Lee HS, "How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetateenhanced MRI?", Eur Radiol, 29, pp.2408~2416 (2019)
- Kim YY, "Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis : performance of LI-RADS version 2018", Radiology, 291, pp.72~80 (2019)
- Obuchowski NA, "Receiver operating characteristic curves and their use in radiology", Radiology, 229, pp.3~8 (2003)
- Gwet K, "Computing inter-rater reliability with the SAS system", Stat Methods Inter-rater Reliability Assess, 3, pp.1~16 (2002)
- Hillis SL, "Recent developments in the Dorfman-Berbaum-Metz procedure for multireader ROC study analysis", Acad Radiol, 15, pp.647~661 (2008)
- Dorfman DD, "Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method", Invest Radiol, 27, pp.723~731 (1992)
- Obuchowski NA Jr, "Hypothesis testing of diagnostic accuracy for multiple readers and multiple tests an anova approach with dependent observations", Commun Stat-Simul Comput, 24, pp.285~308 (1995)
- Baek CK, "Hepatocellular carcinoma in patients with chronic liver disease : a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT", Clin Radiol, 67, pp.148~156 (2012)
- Semaan S, "Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid", Eur Radiol, 30, pp.1020~1030 (2020)
- Yoon JH, "Added value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small(10-19 mm)or atypical hepatic observations at contrast-enhanced CT : a prospective comparison", J Magn Reson Imaging, 49, pp.574~587 (2019)
- 정용은, "Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma", Investigative Magnetic Resonance Imaging, 23(4), pp.351~360 (2019), 대한자기공명의과학회
- Park IK, "Pseudoglandular formation in hepatocellular carcinoma determines apparent diffusion coefficient in diffusionweighted MRI", Investig Magn Reson Imaging, 22, pp.79~85 (2018)
- Min JH, "Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the Liver Imaging Reporting and Data System", Hepatology, 68, pp.2254~2266 (2018)
- Lee S, "Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging", Hepatol Int, 14, pp.70~79 (2020)
- Fraum TJ, "Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk : diagnostic performance of the Liver Imaging Reporting and Data System Version 2014", Radiology, 286, pp.158~172 (2018)
- Fowler KJ, "LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma", Abdom Radiol(NY), 43, pp.149~157 (2018)
- Ludwig DR, "Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018", Abdom Radiol (NY), 44, pp.2116~2132 (2019)